Dr. Mazyar Shadman introduces the program on first-line CLL therapy in the era of BTK inhibition, joined by Dr. Andrew Lipsky. Dr. Lipsky addresses the framework for interpreting real-world data and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results